[Current perspective of chemoprevention in breast cancer].
Department of Surgery, Keio University School of Medicine.
Sota
S
Asaga
Hiromitsu
H
Jinno
Michio
M
Sakata
Masaki
M
Kitajima
D051017:Apoptosis Regulatory Proteins; D047072:Aromatase Inhibitors / Q000008:administration & dosage; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015201:Meta-Analysis as Topic; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage*; D011960:Receptors, Estrogen; D012306:Risk; D018570:Risk Assessment; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage*; D013629:Tamoxifen / Q000008:administration & dosage*
D051017:Apoptosis Regulatory Proteins; D047072:Aromatase Inhibitors; C118024:BLID protein, human; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D052246:Cyclooxygenase 2 Inhibitors; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride